Concurrent vismodegib and radiotherapy for recurrent, advanced basal cell carcinoma

JAMA Dermatology

Volumn 151, Issue 9, 2015, Pages 998-1001

  Pollom, Erqi L ^a   Bui, Timothy T ^a   Chang, Anne Lynn S ^a   Colevas, A Dimitrios ^a   Hara, Wendy Y ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VISMODEGIB; ANILIDE; PYRIDINE DERIVATIVE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BASAL CELL CARCINOMA; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CASE REPORT; CAVERNOUS SINUS; CHEMORADIOTHERAPY; CHEMOSURGERY; COMPUTER ASSISTED TOMOGRAPHY; DIPLOPIA; DISEASE DURATION; EYE BIOPSY; HEAD AND NECK CARCINOMA; HUMAN; HUMAN TISSUE; INFRAORBITAL NERVE; MALE; MIDDLE AGED; NERVE BIOPSY; NEUROLOGIC EXAMINATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PARESTHESIA; PERINEURAL INVASION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIATION DOSE; SECONDARY VISUAL CORTEX; TREATMENT RESPONSE; TRIGEMINAL NERVE; TRIGEMINUS NEURALGIA; VESTIBULOCOCHLEAR NERVE; VISUAL ACUITY; VISUAL AREA V3; CANCER STAGING; CARCINOMA, BASAL CELL; FOLLOW UP; PROSPECTIVE STUDY; SKIN NEOPLASMS; TUMOR RECURRENCE;

AGED; ANILIDES; CARCINOMA, BASAL CELL; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROSPECTIVE STUDIES; PYRIDINES; SKIN NEOPLASMS;

EID: 84941313201     PISSN: 21686068     EISSN: 21686084     Source Type: Journal    
DOI: 10.1001/jamadermatol.2015.0326     Document Type: Article

References (17)

1. Mendenhall WM, Amdur RJ, Hinerman RW, Cognetta AB, Mendenhall NP. Radiotherapy for cutaneous squamous and basal cell carcinomas of the head and neck. Laryngoscope. 2009;119(10): 1994-1999.
2. Moeholt K, Aagaard H, Pfeiffer P, Hansen O. Platinum-based cytotoxic therapy in basal cell carcinoma: a review of the literature. Acta Oncol. 1996;35(6):677-682.
3. Sekulic A, Migden MR, Oro AE, et al. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med. 2012;366(23):2171-2179.
4. Gathings RM, Orscheln CS, Huang WW. Compassionate use of vismodegib and adjuvant radiotherapy in the treatment of multiple locally advanced and inoperable basal cell carcinomas and squamous cell carcinomas of the skin. J Am Acad Dermatol. 2014;70(4):e88-e89.
5. Von Hoff DD, LoRusso PM, Rudin CM, et al. Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. N Engl J Med. 2009;361(12): 1164-1172.
6. Chang AL, Solomon JA, Hainsworth JD, et al. Expanded access study of patients with advanced basal cell carcinoma treated with the Hedgehog pathway inhibitor, vismodegib. J AmAcad Dermatol. 2014;70(1):60-69.
7. LoRusso PM, Rudin CM, Reddy JC, et al. Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors. Clin Cancer Res. 2011;17(8):2502-2511.
8. Rudin CM, Hann CL, Laterra J, et al. Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449. N Engl J Med. 2009;361(12):1173-1178.
9. Zhu GA, Sundram U, Chang AL. Two different scenarios of squamous cell carcinoma within advanced basal cell carcinomas: cases illustrating the importance of serial biopsy during vismodegib usage. JAMA Dermatol. 2014;150(9):970-973.
10. Iarrobino A, Messina JL, Kudchadkar R, Sondak VK. Emergence of a squamous cell carcinoma phenotype following treatment of metastatic basal cell carcinoma with vismodegib. J AmAcad Dermatol. 2013;69(1):e33-e34.
11. Orouji A, Goerdt S, Utikal J, Leverkus M. Multiple highly and moderately differentiated squamous cell carcinomas of the skin during vismodegib treatment of inoperable basal cell carcinoma. Br J Dermatol. 2014;171(2):431-433.
12. ClinicalTrials.gov. Vismodegib for Treatment of Basal Cell Carcinoma. NCT01543581. https://www .clinicaltrials.gov/ct2/show/NCT01543581. Accessed February 25, 2015.
13. ClinicalTrials.gov. A Study Evaluating the Efficacy and Safety of Vismodegib (GDC-0449) in Operable Basal Cell Carcinoma. NCT01201915. https://www .clinicaltrials.gov/ct2/show/NCT01201915. Accessed February 25, 2015.
14. ClinicalTrials.gov. NCT01835626. Phase II Study of Radiation Therapy and Vismodegib for Advanced Head/Neck Basal Cell Carcinoma. https://www .clinicaltrials.gov/ct2/show/NCT01835626. Accessed February 25, 2015.
15. Chen YJ, Lin CP, Hsu ML, Shieh HR, Chao NK, Chao KS. Sonic hedgehog signaling protects human hepatocellular carcinoma cells against ionizing radiation in an autocrine manner. Int J Radiat Oncol Biol Phys. 2011;80(3):851-859.
16. Sims-Mourtada J, Izzo JG, Apisarnthanarax S, et al. Hedgehog: an attribute to tumor regrowth after chemoradiotherapy and a target to improve radiation response. Clin Cancer Res. 2006;12(21): 6565-6572.
17. Zeng J, Aziz K, Chettiar ST, et al. Hedgehog pathway inhibition radiosensitizes non-small cell lung cancers. Int J Radiat Oncol Biol Phys. 2013;86 (1):143-149.